HLY78|854847-61-3|-陌孚医药/Medlife

您当前的位置：

HLY78

目录号: PC15909 纯度: ≥98%

CAS No. :854847-61-3

商品编号	规格	价格	会员价
PC15909-5mg	5mg	¥1468.04	请登录
PC15909-10mg	10mg	¥2606.80	请登录
PC15909-25mg	25mg	¥5707.52	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

HLY78

中文别名

4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine

英文名称

HLY78

英文别名

4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine;4-Ethyl-5,6-Dihydro-5-methyl-[1,3]dioxolo[4,5-j]phenanthridine

Cas No.

854847-61-3

分子式

C₁₇H₁₇NO₂

分子量

267.32

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research.

性状

Solid

IC50 & Target[1][2]

Wnt/β-catenin

体外研究(In Vitro)

HLY78 inhibits apoptosis in tumor cells and embryonic cells caused by carbon ion radiation through activation of the Wnt/β-catenin pathway.
HLY78 (20 μM, 0-48 h) significantly increases the colony formation ability by 2.78-fold and 2.88-fold for HGC-27 and AGS cells compared with the controls.
HLY78 (20 μM, 0-48 h) elevates the migration ability of HGC-27 and AGS cells.
HLY78 significantly increases TNKS expression, which is ameliorated by Dihydroartemisinin (HY-N0176).

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

HLY78 (0-1.8 mg/kg, Intranasal injection, once) attenuates neuronal apoptosis and improves neurological deficits through the LRP6/GSK3β/β-catenin signaling pathway after SAH (subarachnoid hemorrhage) in rats.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats (280-310 g, n=9/group, SAH model)
Dosage:	0, 0.2, 0.6, and 1.8 mg/kg
Administration:	Intranasal injection, once, at 1 h post-SAH (subarachnoid hemorrhage)
Result:	Significantly attenuated the short-term and long-term neurobehavioral deficits, as well as the neuronal apoptosis after SAH at 0.6 mg/kg. Successfully delivered into the brain via intranasal administration at 0.6 mg/kg and was sufficient to significantly increase the phosphorylation of LRP6. Reversed the changes of the Bcl-2, Bax, and cleaved caspase 3 levels.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

[1]. Wang S, et al. Small-molecule modulation of Wnt signaling via modulating the Axin-LRP5/6 interaction. Nat Chem Biol. 2013 Sep;9(9):579-85. [Information]

[2]. Luo X, et al. HLY78 Attenuates Neuronal Apoptosis via the LRP6/GSK3β/β-Catenin Signaling Pathway After Subarachnoid Hemorrhage in Rats. Neurosci Bull. 2020 Oct;36(10):1171-1181. [Information]

[3]. Ma Y, et al. Dihydroartemisinin suppresses proliferation, migration, the Wnt/β-catenin pathway and EMT via TNKS in gastric cancer. Oncol Lett. 2021 Oct;22(4):688. [Information]

溶解度数据

体外研究:

DMSO : 26 mg/mL (97.26 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7408 mL	18.7042 mL	37.4083 mL
5 mM	0.7482 mL	3.7408 mL	7.4817 mL
10 mM	0.3741 mL	1.8704 mL	3.7408 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation